Sotac Pharmaceuticals Limited (NSE:SOTAC)

Market Cap	1.54B
Revenue (ttm)	846.72M
Net Income (ttm)	85.60M
Shares Out	11.05M
EPS (ttm)	7.74
PE Ratio	18.05
Forward PE	n/a
Dividend	0.10 (0.07%)
Ex-Dividend Date	Sep 19, 2025

Volume	n/a
Average Volume	3,360
Open	n/a
Previous Close	162.15
Day's Range	n/a
52-Week Range	88.05 - 154.05
Beta	-0.03
RSI	63.98
Earnings Date	Feb 4, 2026

About Sotac Pharmaceuticals

Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The compan...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 127
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SOTAC

Financial Performance

In 2024, Sotac Pharmaceuticals's revenue was 1.00 billion, a decrease of -3.57% compared to the previous year's 1.04 billion. Earnings were 80.27 million, an increase of 87.48%.